Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Leqembi, sold by partners Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) at an annual list price of $26,500, was approved this year under the U.S. Food and Drug Administration's accelerated pathway.

Eisai now expects Leqembi sales to total JPY 42.5 billion for the period, down from JPY 56.5 billion announced in May. Leqembi sales for the first half of Eisai's FY2024 amounted to JPY 16.3 ...

--BioArctic AB's partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion for their fiscal year 2025, corresponding to a 73 percent growth compared to the previous year.

Eisai expects that Leqembi, which is for Alzheimer's, is going to be a trillion dollar product. Lenvima is working on a major foray in combination with Merck's Keytruda into lung cancer.